BofA's Coloplast EPS Forecasts Tick Down Amid 'Soft' Start to New Fiscal Year, Product Recalls

06:12 AM EST, 12/19/2025 (MT Newswires) -- BofA Global Research lowered its EPS forecasts for Coloplast (COLO-B.CO) on Thursday, while keeping the Danish medical devices and services company's buy rating and price objective of 715 Danish kroner unchanged. Citing a "well messaged" slower start to fiscal 2026 with an expected "soft" fiscal first-quarter organic growth amid product recalls, the research firm changed its fiscal 2026 EPS forecast to 25.51 kroner from 25.52 kroner, while those for 2027 and 2028 were also nudged down to 28.87 kroner from 28.95 kroner, and to 32.19 kroner from 32.35 kroner, respectively. "We continue to value Coloplast at a premium to our sector to reflect its best-in-class margins and its leadership positions. We believe that underlying momentum is intact, and reimbursement overhangs have played out. We appreciate the mid-term guide reset, which gives Coloplast more opportunity for beats & raises, and can support a re-rating towards the historical quality multiple," analysts wrote.